Generalized Anxiety Disorder (GAD) Clinical Trials

Find Generalized Anxiety Disorder (GAD) Clinical Trials Near You

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment

Status: Recruiting
Location: See all (51) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Provide written informed consent before the initiation of any study specific procedures;

• Male or female patients ≥ 18 years of age;

• At Screening, meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria for moderate or severe GAD (current GAD) as confirmed by the Investigator or Sponsor-approved rater using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT), and meets all of the following at Screening and Baseline:

‣ HAM-A Total score of ≥ 22;

⁃ HAM-A Items 1 (anxious mood) and 2 (tension) scores ≥ 2;

⁃ CGI-S score of ≥ 4;

• History of inadequate response (\< 50% improvement in anxiety symptoms as measured by the modified Antidepressant Treatment Response Questionnaire \[ATRQ\] for GAD) to at least 1 GAD-approved treatment (ie, one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone) taken at an adequate dose (at least a minimum total daily dose of paroxetine 20 milligrams \[mg\], venlafaxine XR 75 mg, duloxetine 60 mg, escitalopram 10 mg, or buspirone 20 mg) and duration (ie, daily for at least 6 weeks) for the treatment of ongoing GAD symptoms;

• Currently having an inadequate response to one of the following GAD-approved treatments: paroxetine, venlafaxine XR, duloxetine, escitalopram, or buspirone taken at an adequate dose (at least a minimum total daily dose of paroxetine 20 mg, venlafaxine XR 75 mg, duloxetine 60 mg, escitalopram 10 mg, or buspirone 20 mg) and duration (ie, for at least 6 weeks prior to Screening) and agrees to continue the same dosing regimen for the duration of the study.

∙ NOTE: The current GAD-approved treatment must be different from the GAD treatment identified as the historical failure.

Locations
United States
California
Behavioral Research Specialists LLC
RECRUITING
Glendale
Sun Valley Research Center
RECRUITING
Imperial
Synergy East
RECRUITING
Lemon Grove
Excell Research Inc
RECRUITING
Oceanside
NRC Research Institute
RECRUITING
Orange
Anderson Clinical Research
RECRUITING
Redlands
Florida
Global Medical Institutes
RECRUITING
Miami
Miami Dade Medical Research Institute
RECRUITING
Miami
Premier Clinical Research
RECRUITING
Miami
Sunshine Medical Solution
RECRUITING
Miami
South Florida Research Inc
RECRUITING
Miami Springs
K2 Medical Research
RECRUITING
Tampa
Georgia
Atlanta Center for Medical Research
RECRUITING
Atlanta
CenExeli Research LLC
RECRUITING
Atlanta
Michigan
Michigan Clinical Research Institute
RECRUITING
Ann Arbor
New Jersey
Bio Behavioral Health
RECRUITING
Toms River
New York
SPRI Clinical Trials, LLC
RECRUITING
Brooklyn
Ohio
Neuro Behavioral Clinical Research
RECRUITING
North Canton
Oklahoma
Sooner Clinical Research
RECRUITING
Oklahoma City
Pennsylvania
Lehigh Center for Clinical Research LLC
RECRUITING
Allentown
Suburban Research Associates
RECRUITING
Media
Texas
Austin Clinical Trial Partners
RECRUITING
Austin
BioBehavioral Research of Austin PC
RECRUITING
Austin
Aims Trials LLC
RECRUITING
Plano
Washington
Northwest Clinical Research Center
RECRUITING
Bellevue
Other Locations
Bulgaria
Medical Center Sv Dimitar Blagoevgrad
RECRUITING
Blagoevgrad
Mental Health Center Prof. Dr. Ivan Temkov
RECRUITING
Burgas
Outpatient care-group practice for specialized psychiatric care Datamed OOD
RECRUITING
Pleven
Medical Center Mentalcare OOD
RECRUITING
Plovdiv
Mental Health Center - Rousse
RECRUITING
Rousse
DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
RECRUITING
Sofia
Medical Center Hera EOOD
RECRUITING
Sofia
Medical Center Intermedica, OOD
RECRUITING
Sofia
Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sveti Naum
RECRUITING
Sofia
Medical center - VAS OOD
RECRUITING
Targovishte
Diagnostic Consulting Center Mladost - M Varna
RECRUITING
Varna
Diagnostic Consulting Center Mladost - M Varna 1
RECRUITING
Varna
Mental Health Center - Vratsa EOOD
RECRUITING
Vratsa
Poland
Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
RECRUITING
Bialystok
Przychodnia Srodmiescie SP. z o.o.
RECRUITING
Bydgoszcz
Specjalistyczna Praktyka Lekarska Piotr Zalitacz
RECRUITING
Gorlice
Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
RECRUITING
Leszno
Filip Rybakowski Specjalistyczna Praktyka Lekarska
RECRUITING
Poznan
Agnieszka Nowakowska Rudzka Gabinet Lekarski TCP Neuromed
RECRUITING
Torun
Serbia
Institute of Mental Health Serbia
RECRUITING
Belgrade
University Clinical Center of Serbia
RECRUITING
Belgrade
University Clinical Center of Serbia 1
RECRUITING
Belgrade
University Clinical Hospital Center Dr Dragisa Misovic- Dedi
RECRUITING
Belgrade
Special Neuropsychiatric Hospital Kovin
RECRUITING
Kovin
University Clinical Center Kragujevac
RECRUITING
Kragujevac
Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
RECRUITING
Novi Kneževac
Contact Information
Primary
Study Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Time Frame
Start Date: 2024-08-05
Estimated Completion Date: 2027-10-21
Participants
Target number of participants: 705
Treatments
Experimental: ITI-1284 10 mg
Experimental: ITI-1284 20 mg
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Intra-Cellular Therapies, Inc.

This content was sourced from clinicaltrials.gov